Holen Sie sich die Stockscreener-App
206.89
0.68%
-1.568
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$208.46
Offen:
$211.86
24-Stunden-Volumen:
443.30K
Relative Volume:
0.37
Marktkapitalisierung:
$30.55B
Einnahmen:
$9.60B
Nettoeinkommen (Verlust:
$1.37B
KGV:
22.20
EPS:
9.3182
Netto-Cashflow:
$2.32B
1W Leistung:
-4.18%
1M Leistung:
+5.99%
6M Leistung:
+10.77%
1J Leistung:
+59.10%
1-Tages-Spanne:
$206.80
$212.00
1-Wochen-Bereich:
$206.80
$219.01
52-Wochen-Spanne:
$121.05
$219.72
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
206.94 | 31.91B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,231.67 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
265.94 | 633.19B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.75 | 461.26B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.27 | 319.99B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.70 | 305.10B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Hochstufung | UBS | Neutral → Buy |
| 2026-04-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
RBC Capital Adjusts Biogen Price Target to $242 From $227, Maintains Outperform Rating - marketscreener.com
Biogen to Webcast from the Alzheimer's Association International Conference (AAIC) July 14, 2026 - Biogen
Jefferies Adjusts Price Target on Biogen to $255 From $210 - marketscreener.com
Analyst recommendations: Ferguson, Medpace, Biogen, Crowdstrike, Take-Two… - marketscreener.com
Biogen Inc (MEX:BIIB) Stock Price, Trades & News - GuruFocus
Biogen (BIIB) Hosts Webinar on ALS Research - GuruFocus
Biogen Inc (BIIB) Shares Fall 3.5% -- GF Value Says Still Overva - GuruFocus
How AAIC 2026 Alzheimer’s Data Releases Could Reframe Biogen (BIIB) Investors’ Long‑Term Thesis - simplywall.st
Grey Matters Takes Delivery of the First Brain Dedicated PET Scanning System for its Flagship NovaScan Neuroimaging Clinic in Florida - GlobeNewswire Inc.
Biogen $18.9 Million Securities Class Action Settlement - Claim Depot
Biogen Inc. (BIIB): Investor Outlook On A Healthcare Giant With A $31.91 Billion Market Cap - DirectorsTalk Interviews
Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now - Yahoo Finance
Biogen's $1 Billion Bet: A Venture-Style Pivot to Undisclosed Immunology - Kavout | AI
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors. - The Motley Fool
H.C. Wainwright Remains a Buy on Biogen (BIIB) - The Globe and Mail
BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers - TradingView
Is Biogen Inc (BIIB) Overvalued After 3.0% Rally? GF Value Says - GuruFocus
Biogen Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
BIIBBiogen Inc Latest SEC Filings - Finviz
Biogen (BIIB) Projects Significant Charges Impacting Q2 and Q3 E - GuruFocus
Biogen projects $164M hit to Q2 results from R&D deals and acquisitions - Seeking Alpha
Biogen Says Research, Milestone Charges to Reduce Earnings in Q2, Q3 - marketscreener.com
Biogen (BIIB) Projects Significant Expenses for 2026 - GuruFocus
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Biogen (NASDAQ: BIIB) projects large 2026 R&D milestone charges hitting EPS - Stock Titan
The Spinraza therapyBiogen Inc. leans on long-term SMA demand - AD HOC NEWS
Amgen or Biogen: Which Biotech Stock Appears Better Poised? - Yahoo Finance
BIIB Stock Price Prediction 2025-2026 | Biogen Inc Forecast - 24/7 Wall St.
Biogen reports steady outlook, analysts weigh Alzheimer’s and neurology pipeline - AD HOC NEWS
Biogen Inc.(NasdaqGS: BIIB) dropped from Russell 1000 Value-Defensive Index - marketscreener.com
Biogen Inc.(NasdaqGS: BIIB) dropped from Russell 1000 Defensive Index - marketscreener.com
Biogen: Key Takeaways From Needham’s Meeting With Top Management - Benzinga
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last? - Yahoo Finance
Biogen to present Alzheimer’s drug data at upcoming conference - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen - Biogen
Biogen puts Alzheimer’s pipeline on display at AAIC 2026 - Stock Titan
BIIB Maintained by Needham -- Price Target Raised to $256 - GuruFocus
The Vumerity from Biogen Inc.oral MS therapy with a quieter side-effect profile - AD HOC NEWS
Biogen Inc. stock outperforms competitors on strong trading day - MSN
Biogen (BIIB) Is Up 9.9% After US$1 Billion RayThera Deal And Salanersen WinHas The Bull Case Changed? - simplywall.st
Biogen shares at a four month high, analysts still watch BIIB - Ad-hoc-news.de
Biogen (BIIB) Research Report - StockStory
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Biogen clears a fresh 52-week high, shares react to RayThera deal and FDA tag - AD HOC NEWS
Enterprise value to revenue forward of Biogen Inc. – MUN:IDP - TradingView
Biogen (BIIB) Is Betting Its Next Phase Of Growth On Four New Drugs - simplywall.st
Biogen Inc (BIIB) Shares Surge 7.0% -- What GF Score of 74 Tells Investors - GuruFocus
Why Biogen (BIIB) Stock Is Up Today - Yahoo Finance
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout - Reuters
Biogen Jumps 6.1% Amid Sector-Wide Rally - AlphaStreet
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biogen Inc-Aktie (BIIB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Keeney Adam | Head of Corporate Development |
May 01 '26 |
Option Exercise |
0.00 |
939 |
0 |
6,820 |
| Godbout Sean | Chief Accounting Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
181 |
0 |
1,396 |
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 12 '26 |
Buy |
195.03 |
3 |
585 |
19,611 |
| Viehbacher Christopher | President and CEO |
Feb 06 '26 |
Option Exercise |
0.00 |
24,461 |
0 |
36,548 |
| Singhal Priya | Head of Development |
Feb 06 '26 |
Option Exercise |
0.00 |
6,900 |
0 |
12,115 |
| Singhal Priya | Head of Development |
Feb 09 '26 |
Sale |
199.83 |
2,660 |
531,548 |
8,043 |
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 06 '26 |
Option Exercise |
0.00 |
8,725 |
0 |
21,016 |
| Kramer Robin | Chief Financial Officer |
Feb 06 '26 |
Option Exercise |
0.00 |
5,003 |
0 |
12,535 |
| Keeney Adam | Head of Corporate Development |
Feb 06 '26 |
Option Exercise |
0.00 |
5,080 |
0 |
6,875 |
| Izzar Rachid | Head of Global Product Strat. |
Feb 06 '26 |
Option Exercise |
0.00 |
6,889 |
0 |
11,786 |
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):